21 . 10 .2024
Press release
ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
17 . 10 .2024
News story
ASDS 2024: Galderma presents data on RelabotulinumtoxinA and Sculptra®
25 . 09 .2024
Press release
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations
17 . 09 .2024
Press release
Galderma reaffirms its leadership in dermatology with extensive presence at EADV 2024
04 . 09 .2024
Press release
Galderma launches Cetaphil Gentle Exfoliating line with Gen-Z it-girl Katie Fang
13 . 08 .2024
Press release
Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis
05 . 08 .2024
Press release
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology